Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2021-09-22
- Target Recruit Count
- 63
- Registration Number
- NCT00837434
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Rochester, Rochester, New York, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- Dermatrials Research
- Target Recruit Count
- 10
- Registration Number
- NCT00833729
- Locations
- 🇨🇦
Dermatrials Research, Hamilton, Ontario, Canada
Preoperative Etanercept Before Inguinal Hernia Surgery
- Conditions
- Interventions
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 77
- Registration Number
- NCT00825344
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, D.C., District of Columbia, United States
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT00802815
- Locations
- 🇺🇸
Washington University Department of Neurology, Saint Louis, Missouri, United States
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 30
- Registration Number
- NCT00800982
- Locations
- 🇺🇸
UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2012-10-04
- Target Recruit Count
- 13
- Registration Number
- NCT00796705
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸Feinstein Institute for Medical Research NS-LIJ, Manhassett, New York, United States
TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 81
- Registration Number
- NCT00789997
Islet After Kidney Transplant for Type 1 Diabetes
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Virginia Commonwealth University
- Registration Number
- NCT00784966
- Locations
- 🇺🇸
Virginia Commonwealth University Health System, Richmond, Virginia, United States
Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2011-07-29
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT00768053
- Locations
- 🇲🇨
Pfizer Investigational Site, Monaco, Monaco
A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy
- Conditions
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 84
- Registration Number
- NCT00733096
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇺🇸Womack Army Medical Center, Fort Bragg, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.